| Previous Close | 77.70 |
| Open | 76.10 |
| Bid | 77.40 x 1800 |
| Ask | 77.00 x 1300 |
| Day's Range | 76.76 - 77.54 |
| 52 Week Range | 71.72 - 87.80 |
| Volume | 1,116,840 |
| Avg. Volume | 12,407,260 |
| Market Cap | 194.847B |
| Beta (5Y Monthly) | 0.41 |
| PE Ratio (TTM) | 27.80 |
| EPS (TTM) | 2.77 |
| Earnings Date | Jul. 29, 2021 |
| Forward Dividend & Yield | 2.60 (3.35%) |
| Ex-Dividend Date | Mar. 12, 2021 |
| 1y Target Est | 94.02 |
- Editor's PickYahoo Finance Video
Former Acting CDC Director on why it's 'really important' to pay attention to COVID-19 variants
Dr. Richard Besser, Former Acting CDC Director, Robert Wood Johnson Foundation President & CEO, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.
- Business Wire
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
- Business Wire
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
Merck and Eisai Receive Priority Review From FDA for KEYTRUDA Plus LENVIMA Applications for Advanced RCC and for Advanced Endometrial Carcinoma
© 2021 Verizon Media. All rights reserved.
